Moloney Securities Asset Management LLC Sells 34,000 Shares of SOPHiA GENETICS SA (NASDAQ:SOPH)

Moloney Securities Asset Management LLC decreased its position in SOPHiA GENETICS SA (NASDAQ:SOPH) by 41.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 47,500 shares of the company’s stock after selling 34,000 shares during the quarter. Moloney Securities Asset Management LLC owned approximately 0.07% of SOPHiA GENETICS worth $146,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Silverberg Bernstein Capital Management LLC acquired a new position in SOPHiA GENETICS during the 4th quarter worth $70,000. Green Alpha Advisors LLC increased its stake in shares of SOPHiA GENETICS by 119.3% in the fourth quarter. Green Alpha Advisors LLC now owns 47,216 shares of the company’s stock worth $145,000 after purchasing an additional 25,686 shares during the period. Finally, Principal Financial Group Inc. lifted its position in shares of SOPHiA GENETICS by 6.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company’s stock worth $5,290,000 after purchasing an additional 86,764 shares during the last quarter. 31.59% of the stock is currently owned by institutional investors and hedge funds.

SOPHiA GENETICS Stock Down 4.4 %

Shares of SOPH opened at $3.68 on Wednesday. SOPHiA GENETICS SA has a 52 week low of $2.70 and a 52 week high of $7.37. The firm has a market capitalization of $240.60 million, a P/E ratio of -3.38 and a beta of 1.03. The company has a 50-day simple moving average of $3.39 and a 200-day simple moving average of $3.55. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.59 and a current ratio of 3.80.

Analyst Ratings Changes

Separately, Craig Hallum initiated coverage on SOPHiA GENETICS in a report on Wednesday, December 18th. They issued a “buy” rating and a $11.00 target price on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $7.40.

SOPHiA GENETICS Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.